Deutetrabenazine (US brand name Austedo®) is a vesicular monoamine transporter 2 (VMAT2) inhibitor. Here is basic information about this medication. Other articles on this website with more advanced information and tips related to this medication are linked to under Related Pages below.
Treatment of chorea associated with Huntington’s disease
Treatment of tardive dyskinesia in adults
A. When patients are not being switched from tetrabenazine (Xenazine®)
1. Chorea associated with Huntington’s disease
Initial: 6 mg/day orally
Recommended: 6 mg – 48 mg/day
Maximum: 48 mg/day
2. Tardive dyskinesia
Initial: 12 mg/day
Recommended: 12 mg– 48 mg/day
Maximum: 48 mg/day
B. When patients are being switched from tetrabenazine (Xenazine®) to deutetrabenazine (Austedo®)[table id=3 /]
Titrate at weekly intervals by 6 mg per day based on reduction of chorea or tardive dyskinesia, and tolerability, up to a maximum recommended daily dosage of 48 mg (24 mg twice daily).
Administer total daily dosages of 12 mg or above in two divided doses.
Administer deutetrabenazine with food.
Patients should swallow whole tablets without chewing, crushing, or breaking tablets.
For patients at risk for QT prolongation, assess the QT interval before and after increasing total deutetrabenazine dosage above 24 mg per day
Dosage forms and strengths
Tablets: 6 mg, 9 mg, and 12 mg
Potential side effects
Please see THIS PAGE for a handout listing both the common and less common side effects of this medication along with the percentages of patients who report them.
Important! Please refer to the full Prescribing Information (see link below) before prescribing this medication.
Citrome L. Deutetrabenazine for tardive dyskinesia: A systematic review of the efficacy and safety profile for this newly approved novel medication-What is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract. 2017 Nov;71(11). doi: 10.1111/ijcp.13030. Epub 2017 Oct 12. Review. PubMed PMID: 29024264.
Anderson KE, Stamler D, Davis MD, Factor SA, Hauser RA, Isojärvi J, Jarskog LF, Jimenez-Shahed J, Kumar R, McEvoy JP, Ochudlo S, Ondo WG, Fernandez HH. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Psychiatry. 2017 Aug;4(8):595-604. doi: 10.1016/S2215-0366(17)30236-5. Epub 2017 Jun 28. PubMed PMID: 28668671.
Fernandez HH, Factor SA, Hauser RA, Jimenez-Shahed J, Ondo WG, Jarskog LF, Meltzer HY, Woods SW, Bega D, LeDoux MS, Shprecher DR, Davis C, Davis MD, Stamler D, Anderson KE. Randomized controlled trial of deutetrabenazine for tardive dyskinesia: The ARM-TD study. Neurology. 2017 May 23;88(21):2003-2010. doi: 10.1212/WNL.0000000000003960. Epub 2017 Apr 26. PubMed PMID: 28446646; PubMed Central PMCID: PMC5440239.
Fernandez HH, Stamler D, Davis MD, Factor SA, Hauser RA, Jimenez-Shahed J, Ondo WG, Jarskog LF, Woods SW, Bega D, LeDoux MS, Shprecher DR, Anderson KE. Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia. J Neurol Neurosurg Psychiatry. 2019 Dec;90(12):1317-1323. doi: 10.1136/jnnp-2018-319918. Epub 2019 Jul 10. PubMed PMID: 31296586.
Copyright © 2017 to 2019, Simple and Practical Medical Education, LLC. All rights reserved. May not be reproduced in any form without express written permission.
Disclaimer: The content on this website is provided as general education for medical professionals. It is not intended or recommended for patients or other laypersons or as a substitute for medical advice, diagnosis, or treatment. Patients must always consult a qualified health care professional regarding their diagnosis and treatment. Healthcare professionals should always check this website for the most recently updated information.